Protalix is a biopharmaceutical company that specializes in the manufacture of recombinant therapeutic proteins through its ProCellEx plant cell-based protein expression system. Using ProCellEx, Protalix is developing a proprietary pipeline of biobetter and biosimilar recombinant proteins that target large, established markets and that rely upon known biological mechanisms of action.

biopharmaceuticals
Public (NYSE:PLX)
Visit Website
Additional Portfolio Companies
Adicet Bio
ARTSaVIT
BioBlast Pharma
Cathworks
cCAM Biotherapeutics
CheckCap
Eloxx Pharmaceuticals
Enlivex Therapeutics
Entera Bio
Eyevensys
EyeYon
Hairstetics
Headsense
Keros Therapeutics
Kite Pharma
Leap Therapeutics
LogicBio Therapeutics
Metabomed
NovellusDX
Novus Therapeutics
Nutrinia
Ocon Medical
PACT Pharma
Pi Therapeutics
Protalix
Raziel Therapeutics
ReWalk
StimatixGI
Sweetch
TargEDys
UroGen
V-Wave
Zolex Therapeutics
June 26, 2015